THE INFLUENCE OF PLASMA LEVEL ALTERATIONS OF INFLAMMATORY, ENDOCRINE AND VASCULAR BIOMARKERS FOR THE FORMATION AND PROGNOSIS OF PULMONARY TUBERCULOSIS COMORBID WITH DIABETES MELLITUS TYPE-2
DOI:
https://doi.org/10.52340/jecm.2025.05.01Keywords:
Pulmonary tuberculosis, diabetes, cytokines, adipocytokines, lipid spectrumAbstract
Tuberculosis (TB) remains as a most disseminated infectious disease resulting in different complications and lethal outcome. Studies conducted in last decades showed the increase frequency of pulmonary tuberculosis (PTB) in subjects suffered by diabetes mellitus type-2 (DMT2).
The goal of the present investigation was to study the modulatory action of inflammatory cytokines (IL-1B, TNFα), vasoactive agents: epoxyeicosatrienoic acids (EETs), endothelin-1 (E-1), vascular endothelium growth factor (VEGF), resistin (R), lipid spectrum, catecholamines (noradrenaline, epinephrine) and endocrine factors – leptin and adiponectin plasma levels alterations in the formation and prognosis of PTB and PTB comorbid with DMT2. Observational study was carried out in 2023-2025 years period in Tbilisi National Center for Tuberculosis and Lung Diseases (Georgia). Recruiting male and female adult patients (18 and more years old, n=50) were divided into 3 groups: a) Healthy volunteers (HV)-n=10; b) Subjects with newly diagnosed PTB-n=20; c) Patients with PTB coincident with DMT2 (PTBDMT2)-n=20.
All patients were involved in this study according inclusion and exclusion criteria. The existence of MTB along with clinical symptoms and X-rays examinations was confirmed by Gene Xpert MTB/RiF ULTRA Test. Plasma concentrations of abovementioned agents as well as glycemic control of fasting glucose, insulin and glycated hemoglobin - (HbA1C%) levels was performed by ELISA Kits method. Insulin resistance (IR) was calculated by HOMA-index using formula: [(fasting glucose (mmol/L X fasting insulin (micromole/L/22,5)]. Receiving results revealed in subjects suffered by PTBDMT2 significantly higher plasma level of cytokines IL-1 31,4 (4,2-60,0) pg/ml, P<0,1534) and TNFα 76,2 (3,5-120,0) pg/ml, P<0,0001), that more expressively positively correlated with elevated concentrations of vasoactive agents – E-1 10,3 (3,5-18,4) pg/ml, P<0,0008), catecholamines, VEGF 917,44 (400,0-1495) pg/ml, P<0,00054), R 43,8(14-259) pg/ml, P<0,03846) and endocrine factor leptin 2,02 (0,34-5,8) pg/ml, P<0,00001), providing marked negative relationship to EETs 6,9 (4,8-9,9) pg/ml and adiponectin 95,47 (18-305) pg/ml, P<0,00694) as compared to the same values of PTB and especially HV groups of patients. Such events were associated with lipid spectrum disorders in PTB and PTBDMT2 patients.
It is suggesting that cytokines, vasoactive and endocrine agents can be considered as potential biomarkers for early diagnostic and assessment of treatment effectiveness and outcome of PTB and PTBDMT2.
Downloads
References
Alsayed S.S.R, Gunosewovo H. Tuberculosis: Pathogenesis, current treatment regimens and new drug targets. Int. J. Mol. Sci. 2023, 24, 5202.
Adefuye M.A.; Manjunatha N.; Ganduri, V.; Rajasekaran K.; Duraiyarasan S.; Adefuye B.O. Tuberculosis and cardiovascular complications: An overview. Cureus 2022, 14, e28268.
World Health Organization. 14 October 2021. Global Tuberculosis Report 2021. Available online: https://www.who.int/publications/i/item/9789240037021 (accessed on 10 October 2024).
Kumar N.P, Moideen K, Banurekha VV, Nair D, Babu S. Plasma proinflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis. Open Forum Infect. Dis. 2019.6 (7):ofz257. doi:1093/ofid/ofz257.
Abbas U, Masood K.I, Khan A, Irfan M, Saifullah N, Jamil B. and Hasan Z. Tuberculosis and diabetes mellitus: Relating immune impact of co-morbidity with challenges in disease management in high burden countries. J. Clin. Tuberc. Other Mycobact. Dis. 2022. doi:10.1016/j.jctube.2022. 100343.
Al-Rifai R.H, Pearson F, Critchley IA, Abu-Raddad L. Association between diabetes mellitus and active tuberculosis: a systematic review and meta-analysis. PLOS One.2017.12 (11):e0187967.
Bisht M.K, Dahiya P, et al. The Cause-effect relation of tuberculosis on incidence of diabetic mellitus. Front in Cell and Infect. Microbiol. 2023. https://doi.org/10.3389/ fcimb 2023.113036.
Chen H, Su L, Bao J, et al. The impact of pulmonary tuberculosis on immunological and metabolic features of diabetic patients. Frontiers. 2022.vol.13. https://doi.org/10.3389/ fimmu.2022. 973391.
Ecrold C, Kumar V, et al. Impact of intermediate hyperglycemia and diabetes on immune dysfunction in tuberculosis. Clinical infectious diseases. 2021, 72 (1): 69-78. https://doi.org/10.1093/cid/ciaa751.
Ergul A. Endothelin-1 and Diabetic Complications: Focus on the Vasculature. Pharmacol. Research. 2011. 63(6): 477-487. Doi: 10.1016/J.Phrs.2011.01.012. PMID: 21292003.
Wang Y, Tang J, Wang R, Chen C, Tan S, Yu F, Tao Y. and Li Y. Sputum endothelin-1 level is associated with active pulmonary tuberculosis and effectiveness of anti-tuberculosis chemotherapy. Exp. Ther. Med. 2016. 11(3): 1104-1108. doi:10.3892/etm.216.2980. PMID: 26998044.
Cardiovascular complications of diabetes: from microvascular to macrovascular pathways. Zakir M, Ahuja N, Surksha MA, et al. Cureus. 2023;15:0. doi: 10.7759/cureus.45835.
Cardiac autonomic neuropathy in newly diagnosed patients with type 2 diabetes mellitus. Siddiqui MS, Dev V, Khandelwal E. Cureus. 2023;15:0. doi: 10.7759/cureus.47366.
Yang N.A, Peng R, Guo Y, et al. The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins. Lipids Health.Dis.2013.12:151.DOI:10.1186/1476-511x-12-151
Margoni A, Perrea D.N, Vlachos I, et al. Serum leptin, Adiponectin and Tumor Necrosis Factor-α in Hyperlipidemic Rats with/without Concomitant Diabetes Mellitus. J. Mol. Med. 2011; 17(1-2):36-40. Doi:10.2119/ molmed. 2010.00167.
Wong S.K., Chin K.Y, Soelaiman I.N. Leptin, Adiponectin and Insulin as Regulators for Energy Metabolism in a Rat Model of Metabolic Syndrome. Sains Malaysiana. 48 (1):2701-2707. http://dx.doi.org/10.17576/jsm-2019-4812-11
Chen B.H, Song Y, et al. Circulating Levels of Resistin and Risk of Type 2 Diabetes in Men and Women: Results From Two Prospective Cohorts. Diabetes Care. 2009. 32:329-334.doi:10.2337/dc08-1625.
Soh A. Z, Tan CTY, MOK E, et al. Adipokines and the risk of active TB: a nested case-control study. Int. J. Tuberc. Lung Dis. 2021. 25(1): 31-35. doi:10.5588/ijtld.20.0300. PMID: 33384042.
WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection.2021 update.2021. https://www.who.Int/publications /i/item/9789240030589.
Kumar N.P, Nair D, Banurekha V.V, Chandra-Kumar D, et al. Type 2 diabetes mellitus coincident with pulmonary or latest tuberculosis result in modulation of adipocytokines. Cytokine. 2016. 79:74-81. doi:10.1016/j.cyto.2015.12.026. PMCID: PMC4729624 PMID: 26771473.
Ji Y, Cao H, Liu Q, Li Z, et al. Screening for pulmonary tuberculosis in high-risk groups of diabetic patients. Int. J. Infect. Dis. 2020. 93:84-89. Doi:10.1016./j.ijid.2020.01.019.
Perin C, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clinical and experimental hypertension. 2001.23(1-2):45-55. DOI:10.1081/CEH-100001196.
Diedrich A, Crossman A.A, Beightol L.A, et al. Baroreflex physiology studied in healthy subjects with very infrequent muscle sympathetic bursts. J. Appl. Physiol (1985). 2012. 114 (2): 203-210. Doi:10.1152/japplphysiol.00509.2011.
Kumar N.P, Moideen K, Nancy A, et al. Heterogenecity in the cytokine profile of tuberculosis-diabetes co-morbidity. Cytokines (2020) 125:154824. Doi: 10.1016/J.cyto.2019.154824
Lopez-Gonzalez J.A, Martinez-Soto J.M, Avila-Cervantes C, et al. Evaluation of systemic inflammation before and after standard anti-tuberculosis treatment in patients with active pulmonary tuberculosis and diabetes mellitus. Cureus. 2024. 16(3):e55391. DOI.10.7759/cureus.55391. PMID: 38562330.
Jayashankar, C.A, Manjunath, B.M, et al. The association of pulmonary tuberculosis, abnormal glucose tolerance, and type 2 diabetes mellitus: A hospital-based cross-sectional study. Cureus 2023;13:e19758.
Kumar N.P, Moideen K, Sivakumara S, Menon P.A, Viswanathanb V, Kornfeld H, Babu S. Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J. of infection. 2017, 74 (1):10-21. https://doi.org/10.1016/J.Jinf.2016.08.021.
Ssekamatte P, Sande O.J, et al. Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility. Frontiers. 2023, vol.14. https//doi.org/10.3389/fimmu.2023. 1122255.
Salunkhe V.S, Patil V.W, Rai P. Lipid profile as a nutritional status marker in tuberculosis. J. Clin. Diagn. Res. 2020, 14, 1-3.
Airhomwanbor K.O, Iyevhobu K.O, Omolumen L.E, et al. Assessment of lipid profile on patients with pulmonary tuberculosis. Acta Sci. Med. Sci. 2023, 7, 198-207.
Chen Z, Kong X, Ma Q, Chen J, Zeng Y, Liu H, Wang X, Liu S. The impact of Mycobacterium tuberculosis on the macrophage cholesterol metabolism pathway. Front. Immunol. 2024, 15, 1402024
Javardi M.S.M, Madani Z, Movahedi A, Karandish M, Abbasi B. The correlation between dietary fat quality indices and lipid profile with Atherogenic index of plasma in obese and non-obese volunteers: A cross-sectional descriptive-analytic case-control study. Lipid Health Dis. 2020, 19, 1-9.
Mani A.P, Shanmugapriya K, Deepak Kanna K, Yadav S. Assessment of lipid profile in patients with pulmonary tuberculosis: An observational study. Cureus 2023, 15, e39244.
Chidambaram V, Zhou L, Castillo J.R, et al. Higher serum cholesterol levels are associated with reduced systemic inflammation and mortality during tuberculosis treatment independent of Body Mass Index. Front. Cardiovasc. Med. 2021, 8, 696517.
Jo Y.S, Han K, Kim D, Yoo J.E, et al. Relationship between total cholesterol level and tuberculosis risk in a nationwide longitudinal cohort. Sci. Rep. 2021, 11, 16254
Ulloque-Badaracco J.R, Hernandez-Bustamante E.A. et al. Atherogenic index of plasma and coronary artery disease: A systematic review. Open Med. 2022, 17, 1915–1926.
Downloads
Published
How to Cite
Issue
Section
